help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ARCHER, S. L.
Right arrow Articles by TUAN DINH-XUAN, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ARCHER, S. L.
Right arrow Articles by TUAN DINH-XUAN, A.

Am. J. Respir. Crit. Care Med., Volume 158, Number 4, October 1998, 1061-1067

Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension

STEPHEN L. ARCHER, KHIER DJABALLAH, MARC HUMBERT, E. KENNETH WEIR, MURIEL FARTOUKH, JOSETTE DALL'AVA-SANTUCCI, JEAN-CHRISTOPHE MERCIER, GERALD SIMONNEAU, and A. TUAN DINH-XUAN

Cardiology Division, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine (Cardiology), Veterans Affairs Medical Center, and University of Minnesota, Minneapolis, Minnesota; Hopital Cochin, Departement de Physiologie Respiratoire, and Hopital Robert Debré, Service de Réanimation Pediatrique, Paris; and Service des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclère, Clamart, France

Dexfenfluramine and fenfluramine greatly increase the risk of developing pulmonary hypertension (PHT). The mechanism of anorexigen-associated PHT (AA-PHT) and the reason PHT occurs in a minority of people exposed are unknown. Anorexigens are weak pulmonary vasoconstrictors, but they become potent when synthesis of the endogenous vasodilator nitric oxide (NO) is suppressed. We hypothesized NO deficiency predisposes affected individuals to develop AA-PHT. A prospective, case-control, study was performed on consecutive patients with AA-PHT (n = 9). Two sex-matched control groups were selected: patients with primary PHT (P-PHT, n = 8) and normal volunteers (n = 12). Lung NO production (VNO) and systemic plasma oxidation products of NO (NOx) were measured at rest and during exercise. AA-PHT developed 17 ± 6 mo after a short course of anorexigen (6 ± 2 mo) and was irreversible. VNO was lower in AA-PHT than in P-PHT and correlated inversely with PVR (p < 0.05). The apparent VNO deficiency may have resulted from increased oxidative inactivation of NO in patients with AA-PHT, as their NOx levels were elevated (p < 0.05) in inverse proportion to VNO (r2 = 0.55; p < 0.02). In susceptible persons, anorexigens can cause an irreversible syndrome of PHT, hypoxemia, and systemic vascular complications after brief exposures. These patients have a relative NO deficiency years after discontinuing the anorexigen, perhaps explaining their original susceptibility.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Sasaki, S. Doi, S. Mizutani, and H. Azuma
Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats
Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1480 - L1487.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. E. Girgis, H. C. Champion, G. B. Diette, R. A. Johns, S. Permutt, and J. T. Sylvester
Decreased Exhaled Nitric Oxide in Pulmonary Arterial Hypertension: Response to Bosentan Therapy
Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 352 - 357.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. R. Morris, G. J. Kato, M. Poljakovic, X. Wang, W. C. Blackwelder, V. Sachdev, S. L. Hazen, E. P. Vichinsky, S. M. Morris Jr, and M. T. Gladwin
Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease
JAMA, July 6, 2005; 294(1): 81 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Bowers, C. Cool, R. C. Murphy, R. M. Tuder, M. W. Hopken, S. C. Flores, and N. F. Voelkel
Oxidative Stress in Severe Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 764 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. R. Morris, S. M. Morris Jr., W. Hagar, J. van Warmerdam, S. Claster, D. Kepka-Lenhart, L. Machado, F. A. Kuypers, and E. P. Vichinsky
Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 63 - 69.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
Y. Mitani, A. Mutlu, J. C. Russell, D. N. Brindley, J. DeAlmeida, and M. Rabinovitch
Dexfenfluramine protects against pulmonary hypertension in rats
J Appl Physiol, November 1, 2002; 93(5): 1770 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Humbert, Z. Deng, G. Simonneau, R.J. Barst, O. Sitbon, M. Wolf, N. Cuervo, K.J. Moore, S.E. Hodge, J.A. Knowles, et al.
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
Eur. Respir. J., September 1, 2002; 20(3): 518 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. SAMB, M. PRETOLANI, A.-T. DINH-XUAN, H. OUKSEL, J. CALLEBERT, C. LISDERO, M. AUBIER, and J. BOCZKOWSKI
Decreased Pulmonary and Tracheal Smooth Muscle Expression and Activity of Type 1 Nitric Oxide Synthase (nNOS) after Ovalbumin Immunization and Multiple Aerosol Challenge in Guinea Pigs
Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 149 - 154.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. ADRIE, M. MONCHI, A. TUAN DINH-XUAN, J. DALL'AVA-SANTUCCI, J.-F. DHAINAUT, and M. R. PINSKY
Exhaled and Nasal Nitric Oxide as a Marker of Pneumonia in Ventilated Patients
Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1143 - 1149.
[Abstract] [Full Text]

Home page
 CirculationHome page
S. Archer and S. Rich
Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress"
Circulation, November 28, 2000; 102(22): 2781 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. D. Michelakis, E. K. Weir, D. P. Nelson, H. L. Reeve, S. Tolarova, and S. L. Archer
Dexfenfluramine Elevates Systemic Blood Pressure by Inhibiting Potassium Currents in Vascular Smooth Muscle Cells
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1143 - 1149.
[Abstract] [Full Text]

Home page
 ThoraxHome page
A J Peacock
Rare diseases bullet 5: Primary pulmonary hypertension
Thorax, December 1, 1999; 54(12): 1107 - 1118.
[Full Text]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. L. Reeve, S. L. Archer, M. Soper, and E. K. Weir
Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca2+, independent of membrane potential
Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L662 - L666.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. L. Reeve, D. P. Nelson, S. L. Archer, and E. K. Weir
Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology
Am J Physiol Lung Cell Mol Physiol, February 1, 1999; 276(2): L213 - L219.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society